<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OXYBUTYNIN CHLORIDE - oxybutynin chloride tablet </strong><br>REMEDYREPACK INC. <br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>Oxybutynin chloride tablets USP are a debossed, very <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> blue, round, biconvex, scored tablet containing 5 mg of oxybutynin chloride, USP. Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride. The structural formula appears below:<br><div class="Figure"><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b15f1a2c-dcae-4c3e-923f-ec81078ba3c4&amp;name=MM1.jpg"></div>
<br><br>C22H31NO3HCl M.W. 393.9<br>Oxybutynin chloride is a white crystalline solid. It is readily soluble in water and acids, but relatively insoluble in alkalis.<br>Oxybutynin chloride tablets USP also contain calcium stearate, microcrystalline cellulose, anhydrous lactose, sodium starch glycolate and FD&amp;C Blue #1 Aluminum Lake.<br>Oxybutynin chloride tablets USP are for oral administration.<br>Meets USP Dissolution Test 2.<br>Therapeutic Category: Antispasmodic, anticholinergic.<br><br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects).<br>Oxybutynin chloride relaxes bladder smooth muscle. In patients with conditions characterized by involuntary bladder contractions, cystometric studies have demonstrated that oxybutynin chloride increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void. Oxybutynin chloride thus decreases urgency and the frequency of both <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinent</span> episodes and voluntary urination.<br>Antimuscarinic activity resides predominately in the R-isomer. A metabolite, desethyloxybutynin, has pharmacological activity similar to that of oxybutynin in invitro studies.<br><br>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3"></a><p></p>
<h1>PHARMACOKINETICS</h1>Absorption<br>Following oral administration of oxybutynin chloride tablets, oxybutynin is rapidly absorbed achieving Cmax within an hour, following which plasma concentration decreases with an effective half-life of approximately 2 to 3 hours. The absolute bioavailability of oxybutynin is reported to be about 6% (range 1.6 to 10.9%) for the tablets. Wide interindividual variation in pharmacokinetic parameters is evident following oral administration of oxybutynin.<br>The mean pharmacokinetic parameters for R- and S-oxybutynin are summarized in Table 1. The plasma concentration-time profiles for R- and S-oxybutynin are similar in shape; Figure 1 shows the profile for R-oxybutynin.<br><br>Table 1 Mean (SD) R- and S-Oxybutynin Pharmacokinetic Parameters Following Three Doses of Oxybutynin Chloride 5 mg Administered Every 8 Hours (n=23)<br>Parameters (units)R-OxybutyninS-OxybutyninCmax (ng/mL)3.6 (2.2)7.8 (4.1)Tmax (h)0.89 (0.34)0.65 (0.32)AUCt (ng22.6 (11.3)35 (17.3)AUCinf (ng24.3 (12.3)37.3 (18.7)<div class="Figure"><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b15f1a2c-dcae-4c3e-923f-ec81078ba3c4&amp;name=MM2.jpg"></div>
<br><br>Figure 1. Mean R-oxybutynin plasma concentrations following three doses of oxybutynin chloride 5 mg administered every 8 hours for 1 day in 23 healthy adult volunteers<br>Oxybutynin chloride steady-state pharmacokinetics were also studied in 11 pediatric patients with detrusor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">overactivity</span> associated with a neurological condition (e.g., <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span>). These pediatric patients were on oxybutynin chloride tablets with total daily dose ranging from 7.5 mg to 15 mg (0.22 to 0.53 mg/kg). Overall, most patients (86.9%) were taking a total daily oxybutynin chloride dose between 10 mg and 15 mg. Sparse sampling technique was used to obtain serum samples. When all available data are normalized to an equivalent of 5 mg twice daily oxybutynin chloride, the mean pharmacokinetic parameters derived for R- and S-oxybutynin and R- and S-desethyloxybutynin are summarized in Table 2. The plasma-time concentration profiles for R- and S-oxybutynin are similar in shape; Figure 2 shows the profile for R-oxybutynin when all available data are normalized to an equivalent of 5 mg twice daily.<br><br>Table 2 MeanSD R- and S-Oxybutynin and R- and S-Desethyloxybutynin Pharmacokinetic Parameters In Children Aged 5 to 15 Following Administration of 7.5 mg to 15 mg Total Daily Dose of Oxybutynin Chloride Tablets (N=11)<br><span class="Underline">*</span>Reflects Cmax for pooled data<span class="Underline"></span>AUC0-end of dosing intervalAll Available Data Normalized to an Equivalent of Oxybutynin Chloride Tablets 5 mg BID or TID at Steady StateR-OxybutyninS-OxybutyninR-DesethyloxybutyninS-DesethyloxybutyninCmax<span class="Underline">*</span>(ng/mL)6.13.210.17.555.417.928.210Tmax (hr)1122AUC<span class="Underline"></span>(ng.hr/mL)19.87.428.412.7238.877.6119.550.7<div class="Figure"><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b15f1a2c-dcae-4c3e-923f-ec81078ba3c4&amp;name=MM3.jpg"></div>
<br><br>Figure 2. Mean steady-state (R-oxybutynin plasma concentrations following administration of total daily oxybutynin chloride tablet dose of 7.5 mg to 15 mg (0.22 mg/kg to 0.53 mg/kg) in children 5 to 15 years of age.Plot represents all available data normalized to the equivalent of oxybutynin chloride 5 mg BID or TID at steady state<br><br><span class="Bold">Food Effects<br></span>Data in the literature suggests that oxybutynin solution coadministered with food resulted in a slight delay in absorption and an increase in its bioavailability by 25% (n=18)1.<br><br><span class="Bold">Distribution<br></span>Plasma concentrations of oxybutynin decline biexponentially following intravenous or oral administration. The volume of distribution is 193 L after intravenous administration of 5 mg oxybutynin chloride.<br><br><span class="Bold">Metabolism<br></span>Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4 found mostly in the liver and gut wall. Its metabolic products include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and desethyloxybutynin, which is pharmacologically active.<br><br><span class="Bold">Excretion<br></span>Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Also, less than 0.1% of the administered dose is excreted as the metabolite desethyloxybutynin.<br><br>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>Oxybutynin chloride was well tolerated in patients administered the drug in controlled studies of 30 days'duration and in uncontrolled studies in which some of the patients received the drug for 2 years<br><br>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>Oxybutynin chloride tablets USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex <span class="product-label-link" type="condition" conceptid="199075" conceptname="Neurogenic bladder">neurogenic bladder</span> (i.e., urgency, frequency, urinary leakage, <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>).<br><br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>Oxybutynin chloride is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and in patients who are at risk for these conditions.<br>Oxybutynin chloride is also contraindicated in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug substance or other components of the product.<br><br>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, lips, tongue and/or larynx has been reported with oxybutynin. In some cases, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> occurred after the first dose. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with upper airway <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, oxybutynin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.<br><br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<span class="Bold">Central Nervous System Effects<br></span>Oxybutynin is associated with anticholinergic central nervous system (CNS) effects (see<span class="Underline">ADVERSE REACTIONS</span>). A variety of CNS anticholinergic effects have been reported, including <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Patients should be monitored for signs of anticholinergic CNS effects, particularly in the first few months after beginning treatment or increasing the dose. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.<br>Oxybutynin chloride should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> treated with <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors due to the risk of aggravation of symptoms.<br><br><span class="Bold">General<br></span>Oxybutynin chloride should be used with caution in the frail elderly, in patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.<br>Oxybutynin chloride may aggravate the symptoms of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, and <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span><br></span>Oxybutynin chloride should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (see<span class="Underline">CONTRAINDICATIONS</span>).<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span><br></span>Oxybutynin chloride should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention (see<span class="Underline">CONTRAINDICATIONS</span>).<br>Administration of oxybutynin chloride to patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> may suppress intestinal motility to the point of producing a <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and precipitate or aggravate toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, a serious complication of the disease.<br>Oxybutynin chloride, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, and intestinal atony.<br>Oxybutynin chloride should be used with caution in patients who have <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span> and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.<br><br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-9"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>Patients should be informed that oxybutynin may produce <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> that could result in life-threatening airway obstruction. Patients should be advised to promptly discontinue oxybutynin therapy and seek immediate medical attention if they experience <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the tongue, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the laryngopharynx, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>.<br>Patients should be informed that <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>) can occur when anticholinergics such as oxybutynin chloride are administered in the presence of high environmental temperature.<br>Because anticholinergic agents such as oxybutynin may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>), or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, patients should be advised to exercise caution.<br>Patients should be informed that alcohol may enhance the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> caused by anticholinergic agents such as oxybutynin.<br><br>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-10"></a><p></p>
<h1>DRUG INTERACTIONS</h1>The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.<br>Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index.<br>Mean oxybutynin chloride plasma concentrations were approximately 3 to 4 fold higher when oxybutynin chloride was administered with ketoconazole, a potent CYP3A4 inhibitor.<br>Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). The clinical relevance of such potential interactions is not known. Caution should be used when such drugs are coadministered.<br><br>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-11"></a><p></p>
<h1>CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY</h1>A 24 month study in rats at dosages of oxybutynin chloride of 20, 80, and 160 mg/kg/day showed no evidence of carcinogenicity. These doses are approximately 6, 25, and 50 times the maximum human exposure, based on surface area.<br>Oxybutynin chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae and <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium test systems.<br>Reproduction studies using oxybutynin chloride in the hamster, rabbit, rat, and mouse have shown no definite evidence of impaired fertility.<br><br>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-12"></a><p></p>
<h1>PREGNANCY</h1>Category B. Reproduction studies using oxybutynin chloride in the hamster, rabbit, rat, and mouse have shown no definite evidence of impaired fertility or harm to the animal fetus. The safety of oxybutynin chloride administered to women who are or who may become pregnant has not been established. Therefore, oxybutynin chloride should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards.<br><br>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-13"></a><p></p>
<h1>NURSING MOTHERS</h1>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when oxybutynin chloride is administered to a nursing woman.<br><br>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-14"></a><p></p>
<h1>PEDIATRIC USE</h1>The safety and efficacy of oxybutynin chloride administration have been demonstrated for pediatric patients 5 years of age and older (see<span class="Underline">DOSAGE AND ADMINISTRATION</span>).<br>The safety and efficacy of oxybutynin chloride tablets were studied in 30 children in a 24 week, open-label trial. Patients were aged 5 to 15 years, all had symptoms of detrusor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">overactivity</span> in association with a neurological condition (e.g., <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span>), all used clean intermittent catheterization, and all were current users of oxybutynin chloride. Study results demonstrated that the administration of oxybutynin chloride was associated with improvement in clinical and urodynamic parameters.<br>At total daily doses ranging from 5 mg to 15 mg, treatment with oxybutynin chloride tablets was associated with an increase from baseline in mean urine volume per catheterization from 122 mL to 145 mL, an increase from baseline in mean urine volume after morning awakening from 148 mL to 168 mL, and an increase from baseline in the mean percentage of catheterizations without a leaking episode from 43% to 61%. Urodynamic results in these patients were consistent with the clinical results. Treatment with oxybutynin chloride tablets was associated with an increase from baseline in maximum cystometric capacity from 230 mL to 279 mL, a decrease from baseline in mean detrusor pressure at maximum cystometric capacity from 36 cm H20 to 33 cm H20, and a reduction in the percentage of patients demonstrating uninhibited detrusor contractions (of at least 15 cm H20) from 39% to 20%.<br>As there is insufficient clinical data for pediatric populations under age 5, oxybutynin chloride is not recommended for this age group.<br><br>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-15"></a><p></p>
<h1>GERIATRIC USE</h1>Clinical studies of oxybutynin chloride did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified diffrences in responses between healthy elderly and younger patients; however, a lower initial starting dose of 2.5 mg given 2 or 3 times a day has been recommended for the frail elderly due to a prolongation of the elimination half-life from 2 to 3 hours to 5 hours. 2,3,4 In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, andof the concomitant disease or other drug therapy.<br><br>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-16"></a><p></p>
<h1>ADVERSE REACTIONS</h1>The safety and efficacy of oxybutynin chloride was evaluated in a total of 199 patients in three clinical trials. These participants were treated with oxybutynin chloride 5 to 20 mg/day for up to 6 weeks. Table 3 shows the incidence of adverse events judged by investigators to be at least possibly related to treatment and reported by at least 5% of patients.<br><br>Table 3 Incidence (%) of Adverse Events Reported by5% of Patients Using Oxybutynin Chloride (5 to 20 mg/day)<br>Body SystemAdverse EventOxybutynin Chloride (5 to 20 mg/day) (n=199)<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and InfestationsUrinary tract infection6.5%Psychiatric DisordersInsomnia5.5%Nervousness6.5%Nervous System DisordersDizziness16.6%Somnolence14%Headache7.5%Eye DisordersBlurred vision9.6%Gastrointestinal DisordersDry mouth71.4%Constipation15.1%Nausea11.6%Dyspepsia6%Renal and Urinary DisordersUrinary Hesitation8.5%Urinary Retention6%The most common adverse events reported by patients receiving oxybutynin chloride 5 to 20 mg/day were the expected side effects of anticholinergic agents. The incidence of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> was dose-related.<br>In addition, the following adverse events were reported by 1 to &lt;5% of patients using oxybutynin chloride (5 to 20 mg/day) in all studies. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>; Metabolism and Nutrition Disorders: <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>; Psychiatric Disorders: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>; <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4172302" conceptname="Sinus headache">sinus headache</span>; <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">keratoconjunctivitis sicca</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>; <span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4217221" conceptname="Nodal rhythm disorder">sinus arrhythmia</span>; <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>: <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">nasal dryness</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">dry throat</span>, <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>; <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">aptyalism</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="44784165" conceptname="Coating of mucous membrane of tongue">tongue coated</span>; Skin and Subcutaneous Tissue Disorders: <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, pruritis; Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>; Renal and Urinary Disorders: <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>; General Disorders and Administration Site Conditions: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; Investigations: <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span>, blood glucose increased, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span>; Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications: <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>.<br><br><span class="Bold">Postmarketing Surveillance<br></span><br><br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-17"></a><p></p>
<h1>OVERDOSAGE</h1>Treatment should be symptomatic and supportive. Activated charcoal as well as a cathartic may be administered.<br>Overdosage with oxybutynin chloride has been associated with anticholinergic effects including central nervous system excitation (e.g., <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>), <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. Other symptoms may include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.<br>Ingestion of 100 mg oxybutynin chloride in association with alcohol has been reported in a 13-year-old boy who experienced <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, and a 34 year old woman who developed <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, followed by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> on awakening, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">retention of urine</span>. Both patients fully recovered with symptomatic treatment.<br><br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-18"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>Adults: The usual dose is one 5 mg tablet two to three times a day. The maximum recommended dose is one 5 mg tablet four times a day. A lower starting dose of 2.5 mg two or three times a day is recommended for the frail elderly.<br>Pediatric patients over 5 years of age: The usual dose is one 5 mg tablet two times a day. The maximum recommended dose is one 5 mg tablet three times a day.<br><br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-19"></a><p></p>
<h1>HOW SUPPLIED</h1>Oxybutynin chloride tablets USP.<br>5 mgVery <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> blue, round, biconvex, scored tablets debossed with PLIVA 456. Available in bottles of 100, 500, and 1000 tablets.<br><br>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-20"></a><p></p>
<h1>STORAGE AND HANDLING</h1>Store at 20to 25(68to 77[See USP Controlled Room Temperature].<br>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.<br>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).<br><br>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-21"></a><p></p>
<h1>REFERENCES</h1>1. Yong C et al. Effect of Food on the Pharmacokinetics of Oxybutynin in normal<br>2. Hughes KM et al. Measurement of oxybutynin and its N-desethyl metabolite in<br>plasma, and its application to pharmacokinetic studies in young, elderly and frail<br>3. Ouslander J et al. Pharmacokinetics and Clinical Effects of Oxybutynin in Geriatric<br>4. Yarker Y et al. Oxybutynin: A review of its Pharmacodynamic and Pharmacokinetic<br>6(3): 243-262.<br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>DRUG: Oxybutynin Chloride<br>GENERIC: Oxybutynin Chloride<br>DOSAGE: TABLET<br>ADMINSTRATION: ORAL<br>NDC: 49349-545-02<br>STRENGTH:5 mg<br>COLOR: blue<br>SHAPE: ROUND<br>SCORE: Two even pieces<br>SIZE: 8 mm<br>IMPRINT: 30<br>QTY: 30<br><br><div class="Figure"><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b15f1a2c-dcae-4c3e-923f-ec81078ba3c4&amp;name=MM4.jpg"></div>
<br><br><div class="Figure"><img alt="MM5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b15f1a2c-dcae-4c3e-923f-ec81078ba3c4&amp;name=MM5.jpg"></div>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OXYBUTYNIN CHLORIDE 		
					</strong><br><span class="contentTableReg">oxybutynin chloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49349-545(NDC:50111-456)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXYBUTYNIN CHLORIDE</strong> (OXYBUTYNIN) </td>
<td class="formItem">OXYBUTYNIN CHLORIDE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (TABLET) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PLIVA;456</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49349-545-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071655</td>
<td class="formItem">09/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1e8fd61d-f9be-459b-aa31-1ecf1254f256</div>
<div>Set id: b15f1a2c-dcae-4c3e-923f-ec81078ba3c4</div>
<div>Version: 1</div>
<div>Effective Time: 20110929</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
